NASA SBIR Phase II awards support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in a commercial product. "We're excited about ...

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from ...

Heliospace Heliospace NASA SBIR Phase II awards support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in a commercial product.

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy (ADT). Study participants ...

Actuate Therapeutics, Inc. announced that the topline results from their Phase 2 trial (Actuate-1801 Part 3B) for the treatment of previously untreated metastatic pancreatic ductal adenocarcinoma ...

The oral presentation, titled "Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy", further supports the potential therapeutic ...

CytomX is conducting a focused Phase 1 dose escalation study of CX-801 in metastatic melanoma. The combination arm of the study evaluating CX-801 in combination with KEYTRUDA ® has been initiated ...

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral ...

announced today they have successfully completed enrollment in their phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions ...

announced today they have successfully completed enrollment in their phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions ...

Demonstrating statistically significant increases in both median overall survival and percent of patients reaching one-year survival and beyond, along with a favorable risk-benefit profile in this ...